The Cancer Prevention and Research Institute of Texas has doled out 73 more grants to health care systems and companies in the state. Carter Smith/Courtesy of MD Anderson

The Cancer Prevention and Research Institute of Texas has granted more than $120 million to Houston organizations and companies as part of 73 new awards issued statewide.

The funds are part of nearly $154 million approved by the CPRIT's governing board earlier this month, bringing the organization's total investment in cancer prevention and research to more than $4 billion since its inception.

“Today marks an important milestone for CPRIT and for every Texan affected by cancer,” CEO Kristen Doyle said in a news release. “Texas has invested $4 billion in the fight against one of the world’s greatest public health challenges. Over 16 years, that support has helped Texas lead the search for breakthrough treatments, develop new cancer-fighting drugs and devices, and—most importantly—save tens of thousands of lives through early cancer detection and prevention. Every Texan should know this effort matters, and we’re not finished yet. Together, we will conquer cancer.”

A portion of the funding will go toward recruiting leading cancer researchers to Houston. CPRIT granted $5 million to bring John Quackenbush to Baylor College of Medicine. Quackenbush comes from the Harvard T.H. Chan School of Public Health and is an expert in computational and systems biology. His research focuses on complex genomic data to understand cancer and develop targeted therapies.

The University of Texas M.D. Anderson Cancer Center also received $3 million to recruit Irfan Asangani, an associate professor at the University of Pennsylvania Perelman School of Medicine. His research focuses on how chromatin structure and epigenetic regulation drive the development and progression of cancer, especially prostate cancer.

Other funds will go towards research on a rare, aggressive kidney cancer that impacts children and young adults; screening programs for breast and cervical cancer; and diagnostic technology.

In total, cancer grants were given to:

  • The University of Texas M.D. Anderson Cancer Center: $29.02 million
  • Baylor College of Medicine: $15.04 million
  • The University of Texas Health Science Center at Houston: $9.37 million
  • Texas A&M University System Health Science Center: $1.2 million
  • University of Houston: $900,000

Additional Houston-based companies landed grants, including:

  • Crossbridge Bio Inc.: $15.01 million
  • OncoMAGNETx Inc.: $13.97 million
  • Immunogenesis Inc.: $10.85 million
  • Diakonos Oncology Corporation: $7.16 million
  • Iterion Therapeutics Inc.: $7.13 million
  • NovaScan Inc.: $3.7 million
  • EMPIRI Inc.: $2.59 million
  • Air Surgical Inc.: $2.58 million
  • Light and Salt Association: $2.45 million

See the full list of awards here.

Sustainability, therapeutics, hard tech, and more — all this innovation and more is coming out of Houston startups. Courtesy photos

2024's 5 most-read startup feature stories

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. This past year, InnovationMap featured profiles on dozens of these Houston startups — from health tech to startups fostering community. Here are five Houston startup features that stood out to readers this year — be sure to click through to read the full story.

Houston immuno-oncology company reaches next FDA milestone, heads to phase 2 trial

A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Getty Images

A Houston immuno-oncology company has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

Diakonos Oncology was born in 2016, the brainchild of Baylor researchers already hard at work in the realm of dendritic cell vaccines. Drs. Will Decker, Matt Halpert, and Vanaja Konduri partnered with Dan Faust, a Houston businessman and pharmacist, to bring their treatment to the public, says COO Jay Hartenbach.

The name Diakonos means “deacon or servant in Greek,” he explains. “A lot of companies end up focusing on treating a specific disease or cancer and what you end up having is a significant amount of potential but with a lot of tradeoffs and downsides. And so our goal is we need to eliminate the cancer but we can't harm or dramatically malign the patient in doing so.” Continue reading.

Houston founder taps into AI tech to create game-changing healthy eating platform

A Better Meal — a new app from a Houston founder — gives you all the tools you need to make healthier food choices. Photo via abettermeal.com

After many years of living to eat, a large swath of American society is now facilitating a seismic shift to the healthier alternative, eating to live.

But here’s the rub: eating healthy is confusing, time consuming and, unfortunately, oftentimes pricey.

So, anyone that can come in and cut through the healthy eating machine can carve out a necessary niche in the marketplace.

Enter Houstonian Mark Semmelbeck, founder and CEO of A Better Meal, a platform created to help busy families plan healthy meals easier and to make gradual improvements to their health and well-being.

“My vision is to use rapidly expanding AI technology together with the knowledge and wisdom of an active community to take the stress out of meal planning and improving nutrition,” says Semmelbeck, a seasoned oil and gas executive with over 30 years of experience in founding companies. “While developing the technology for the app, my daughter gave me two beautiful grandkids who both have significant food allergies. Combine that with the fact I now have five cardiac stents and the significance of eating well while paying attention to the details has only grown in importance.” Continue reading.

Hardtech startup moves into Houston area with new Conroe facility, eyes tests in space

FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says. Continue reading.

Houston startup secures IBM partnership for AI-backed consumer tech

IBM and Boxes recently partnered to integrate the IBM watsonx Assistant into Boxes devices, providing a way for consumer packaged brands to find out more than ever about what its customers like and want. Photo courtesy of Boxes

With the help of a new conversational artificial intelligence platform, a Houston startup is ready to let brands get up close and personal with consumers while minimizing waste.

IBM and Boxes recently partnered to integrate the IBM watsonx Assistant into Boxes devices, providing a way for consumer packaged brands to find out more than ever about what its customers like and want.

The Boxes device, about the size of a 40-inch television screen, dispenses products to consumers in a modern and sustainable spin on the old-fashioned large vending machine.

CEO Fernando Machin Gojdycz learned that business from his entrepreneur father, Carlos Daniel Machin, while growing up in Uruguay.

“That’s where my passion comes from — him,” Gojdycz says of his father. In 2016, Gojdycz founded Boxes in Uruguay with some engineer friends. Continue reading.

Houston founder aims to help find your purpose, make strategic connections over a cup of coffee

Cup of Joey has expanded across Houston to help make valuable connections to Houston entrepreneurs. Photo courtesy of Cup of Joey

What is your purpose in life? One Houstonian is asking that question of his fellow entrepreneurs all across town.

Joey Sanchez founded Cup of Joey, a weekly meetup opportunity for innovators, business leaders, and the whole Houston community. The events are a place not only to share a cup of coffee but also their very own mission in life.

It all started in 2021 at the Houston Tech Rodeo, an initiative from Houston Exponential, where Sanchez worked as a director of corporate engagement. Texas had just opened social distancing in public events since the beginning of the COVID-19 pandemic, and Sanchez was finding ways to reconnect the Houston community.

‘We thought what better way than over a cup of coffee?” Since then, Sanchez has connected thousands of people based on purpose every Friday for the past three and a half years. Continue reading.

This week's roundup of Houston innovators includes Atul Varadhachary of Fannin, Natasha Gorodetsky of Product Pursuits, and Jay Hartenbach of Diakonos Oncology. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every Monday, I'm introducing you to three Houston innovators to know — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Atul Varadhachary, managing director of Fannin Innovation

Atul Varadhachary of Fannin joins the Houston Innovators Podcast. Photo via LinkedIn

Commercializing a life science innovation that has the potential to enhance or even save the lives of millions of patients is a marathon, not a sprint. That's how Atul Varadhachary thinks of it, and he's leading an organization that's actively running that race for several different early-stage innovations.

For over a decade, Fannin has worked diligently to develop promising life science innovations — that start as just an idea or research subject — by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The model is different from what you'd see at an accelerator or incubator, and it also varies from the path taken by an academic or research institution.

The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary, managing director at Fannin, says on the Houston Innovators Podcast. Read more.

Natasha Gorodetsky, founder and CEO of Product Pursuits

A product management expert shares how artificial intelligence is affecting the process for the tech and startup worlds. Photo via LinkedIn

For over a year, the tech and business community has been obsessing over artificial intelligence. As Natasha Gorodetsky, the Houston-based founder and CEO of Product Pursuits, writes in a guest column about how the product management community is not an exception.

"Product managers — as well as startup founders leading a product function — more than any other role, face a challenge of bringing new life-changing products to market that may or may not be received well by their users," she writes. "A product manager’s goal is complex — bring value, stay ahead of the competition, be innovative. Yet, the "behind the scenes" grind requires endless decision making and trade offs to inspire stakeholders to move forward and deliver."

She continues in her article to outline the trends of AI for product management. Read more.

Jay Hartenbach, COO of Diakonos Oncology

A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Diakonos

Diakonos Oncology has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

The therapy catalyzes a natural immune response, it’s the patient’s own body that’s fighting the cancer. Hartenbach credits Decker with the idea of educating dendritic cells to attack cancer, in this case, glioblastoma multiforme (GBM), one of the most aggressive cancers with which doctors and patients are forced to tangle.

“Our bodies are already very good at responding very quickly and aggressively to what it perceives as virally infected cells. And so what Dr. Decker did was basically trick the immune system by infecting these dendritic cells with the cancer specific protein and mRNA,” details COO Jay Hartenbach. Read more.

A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Getty Images

Houston immuno-oncology company reaches next FDA milestone, heads to phase 2 trial

green light

A Houston immuno-oncology company has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

Diakonos Oncology was born in 2016, the brainchild of Baylor researchers already hard at work in the realm of dendritic cell vaccines. Drs. Will Decker, Matt Halpert, and Vanaja Konduri partnered with Dan Faust, a Houston businessman and pharmacist, to bring their treatment to the public, says COO Jay Hartenbach.

The name Diakonos means “deacon or servant in Greek,” he explains. “A lot of companies end up focusing on treating a specific disease or cancer and what you end up having is a significant amount of potential but with a lot of tradeoffs and downsides. And so our goal is we need to eliminate the cancer but we can't harm or dramatically malign the patient in doing so.”

How do they do that? Because the therapy catalyzes a natural immune response, it’s the patient’s own body that’s fighting the cancer. Hartenbach credits Decker with the idea of educating dendritic cells to attack cancer, in this case, glioblastoma multiforme (GBM), one of the most aggressive cancers with which doctors and patients are forced to tangle.

“Our bodies are already very good at responding very quickly and aggressively to what it perceives as virally infected cells. And so what Dr. Decker did was basically trick the immune system by infecting these dendritic cells with the cancer specific protein and mRNA,” details Hartenbach.

Jay Hartenbach is the COO of Diakonos Oncology. Photo courtesy of Diakonos Oncology

But GBM isn’t the only cancer on which Diakonos Oncology has its sights set. Other notably stubborn-to-treat cancers that they’re working on include pancreatic cancer and angiosarcoma. The scientists are focused on meeting unmet medical needs, but also realize that treating such cancers would allow for the fastest determination of whether or not the treatment was effective.

The fast track designation, originally received last fall, means that the drug approval time for DOC1021, Diakonos’ glioblastoma vaccine, will be only six months. But Hartenbach highlights an additional boon, the fact that the special designation also allows for more frequent communications with the FDA.

“That’s very helpful for us, right as we're contemplating how to design the upcoming trials. From a business standpoint, it also is incredibly helpful because it provides a third party validation of what we're doing and the results that we're seeing,” he says.

What they’re seeing includes the survival of 13 out of 16 patients from the initial October 2021 enrollment. The three patients who passed away received the lowest dose of DOC1021. Hartenbach says that the remaining patients are thriving, with no serious adverse effects. With a median survival rate of 15 to 21 months, it’s hard to understate the significance of these patients’ success.

Diakonos Oncology is headquartered in Houston, with a staff of 10 in Space City and an additional eight distributed employees. Hartenbach says that the company’s hometown has been instrumental in its success. He mentions that the robust innovation of the Texas Medical Center meant that as the company has grown, there has never been a motivation to leave Houston.

“You're having a lot of both investment and companies actually moving to Houston,” Hartenbach says. “So we’ve been fortunate to have started there. There are bigger traditional biotech hubs, San Diego, Boston, and San Francisco, but Houston really is now putting itself on the map and it's getting a lot of attention.”

One of the companies responsible for that improved reputation? Diakonos Oncology and its promising approach to aggressive cancers.

This year, seven of the 10 most-promising life science companies are based in Houston. Photo courtesy of Rice Alliance

Houston startups dominate ‘most-promising’ companies announcement at annual event

on the list

Rice University played host this week to the 12th annual Texas Life Science Forum, where life science leaders and startup founders could network, learn and present pitches on their solutions to a wide array of health-related issues.

Hosted by Rice Alliance for Technology and Entrepreneurship and BioHouston on November 7, the event brought together more than 600 attendees for a series of keynote speakers and panels. This year, 45 early-stage therapeutic, diagnostic, medical device and digital health companies—many of which are based in Houston—also pitched their concepts.

Fort Worth-based AyuVis Research walked away from the event with the two top recognitions: The Michael E. DeBakey Memorial Life Science Award and the People's Choice Award. The company, which has developed a small molecule immunotherapy targeting bronchopulmonary dysplasia (BPD) in preterm neonates and other respiratory disorders. The company is raising a $20 million Series A round to support its clinical development and is slated to pitch at IGNITE Health’s Fire Pitch 2023 today, November 9, at the Ion.

Each year the Rice Alliance and BioHouston also name its 10 most promising life science companies, selected by investors—seven out of 10 of which are based in Houston. This year's selection included the following companies, in alphabetical order:

  • 7 Hills Pharma: This Houston-based clinical stage immunotherapy company has developed the concept of allosteric activation of integrins to facilitate cell adhesion and promote immune responses. The concept has uses in preventing infection and cancer, and increasing the effectiveness of oncology drugs and infectious disease vaccines.
  • Bairitone Health: This Houston-based company is building a scalable diagnostic system for sleep apnea anatomy utilizing home-use wearable, passive Sonar technology and AI techniques.
  • Diakonos Oncology: Also based in Houston, Diakonos' Dendritic Cell Vaccine was awarded the FDA’s Fast Track designation. The clinical-stage biotech company's immunotherapies have shown early successes for hard-to-reach, aggressive cancers like Glioblastoma Multiforme.
  • Mongoose Bio: With more than 20 years of research, Mongoose specializes in T cell-based therapies for diverse solid tumors TCR-based therapies in cancer patients. The Houston-based company has developed an immunopeptidome discovery platform for TCR-based therapies in cancer patients.
  • Nandi Life Sciences: Nandi is developing antibodies for Avastin-resistant ovarian cancer, with
  • further application in breast, colorectal and lung cancer. The company is based out of Texas Medical Center Innovation.
  • NKILT Therapeutics: This Houston-based company's seed-stage cell therapy has applications in solid tumors, such as colorectal cancer, ovarian cancer, clear cell renal carcinoma, endometrial
  • cancer and more. It is developing a novel and proprietary Chimeric ILT-Receptor.
  • NuVision Biotherapies: Based in the United Kingdom, NuVision has developed and proven a treatment for dry eye disease. It's known for its Omnigen and OmniLenz products and is raising a series A to scale, take the business to profitability and exit.
  • Panakeia Technologies: Also based in the UK, Panakeia has developed an AI-based software that can provide multi-omic biomarkers in minutes. Currently this process takes days or weeks. It's RuO platform can identify 4,500 known multi-omics cancer markers.
  • Taurus Vascular: A recent spin-out of the Texas Medical Center Innovation Biodesign program, Taurus is developing a novel, catheter-based solution for treating endoleaks, which can be related to aortic aneurysms.
  • YAP Therapeutics: The only California-based company to make the cut, this preclinical-stage biotech develops genetic medicines that leverage the company’s tissue renewal and regeneration platform to reverse and cure severe diseases, including heart failure, pulmonary diseases, retinal degeneration and hearing loss.

Last year, Bairitone Health took home the DeBakey and People's Choice awards.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Energy AI company opens first U.S. office at Houston’s the Ion

Building on its partnership with Houston-based oilfield services provider Halliburton, energy-sector AI company Shape Digital recently opened an office at The Ion. It’s the company’s first U.S. location.

Shape Digital’s workforce in Houston includes employees specializing in tech support, business development and client services. The company’s local hiring projections and headcount weren’t available. The new office will be located within Industrious at the Ion, according to Rice Alliance.

A key driver of the new Houston office: The company forecasts North America will account for more than 20 percent of its business in 2027.

“North America is a critical market for industrial innovation, and Houston sits at the center of companies driving that progress,” Caio Sene, vice president of client services at Shape Digital, said in a release. “Growing our presence here allows us to work alongside operators as they look for practical ways to turn existing operational data into clear recommendations for what to do next.”

Shape Digital, which also has offices in Singapore and Brazil, develops decision-making platforms for the oil and gas sector.

The Ion District office gives Shape Digital a presence close to Halliburton’s headquarters. In May, the two companies forged a partnership to combine Halliburton’s Digital Field Solverdecision-making system with Shape Digital’s AI portfolio.

Shape Digital layers AI software atop existing operations data rather than replacing legacy systems or adding new software.

The company’s suite of AI agents draws on more than 200 operations-monitoring algorithms, continually learning from company and industry data. The suite comprises four products: Shape Aura, Shape Lighthouse, Shape Lumen and Shape Reef.

Shape Digital says that by working with a customer’s existing operations data, it can deliver ROI in less than two months without any additional investment in equipment or infrastructure.

The company is a 2021 spinoff of Japan-based Modec. Modec builds, owns, and operates floating offshore oil and gas production facilities. Its Modec America subsidiary is based in Houston.

Meet the esteemed judges for the 2026 Houston Innovation Awards

Meet The Judges

Editor's note: Judging is now underway for the 2026 Houston Innovation Awards, and it's time to meet the decision makers.

Our 2026 judging panel comprises past award winners who represent a variety of industries and areas of expertise. They are joined by InnovationMap's interim editor. All are deeply engaged in the Houston innovation ecosystem.

Our judging panel will review all nominee applications submitted across 10 prestigious categories. They will determine the 2026 finalists in all categories, and they will select the winners in all but one category — our people's choice award for Startup of the Year.

The sixth annual Houston Innovation Awards program will be presented in an all-digital format in 2026. We will announce this year's finalists and feature their stories throughout our special editorial series this fall. Then, stay tuned as we reveal the 2026 Houston Innovation Awards winners on InnovationMap.com in mid-November.

Sagar Dalal, Fervo Energy, 2025 Scaleup of the Year

Sagar Dalal

Sagar Dalal serves as chief of staff at Fervo Energy, a company pioneering the commercialization of next-generation geothermal power. In this role, he helps translate the CEO’s vision and priorities into execution, leading cross-functional strategic initiatives that support the company’s growth and operations.

Dalal brings nearly eight years of experience in structural engineering and project management from his time at Thornton Tomasetti and Tesla, where he engineered and built a wide range of infrastructure projects ranging from stadiums to manufacturing facilities. He holds an MBA from Stanford University and an MS in Civil Engineering from Texas A&M University. He is also a licensed professional engineer.

Aaron Fitzgerald, Mars Materials, 2025 Minority-founded Business of the Year

Aaron Fitzgerald

Aaron Fitzgerald is a three-time founder and carbon removal entrepreneur focused on reimagining how we make things. As the CEO of Mars Materials, he leads a team working to commercialize technologies that sequester captured carbon into industrial supply chains.

His vision for a defossilized future is shaped by a unique path through both policy, including a tenure in the United States Senate, and deep carbontech, with fellowships at The Lewis Latimer program, Breakthrough Energy, Prime Coalition, and Carbon 180.

Tatiana Fofanova, Koda Health, 2025 Health Tech Business of the Year

Tatiana Fofonova

Tatiana Fofanova, PhD, is the co-founder and CEO of Koda Health, an AI-enhanced patient decision support platform designed to make advance care planning (ACP) scalable, accessible, and patient-centered for patients with serious illness.

After earning her PhD in Translational Medicine at Baylor College of Medicine, she joined Texas Medical Center (TMC) as a Founder-in-Residence. It was there that she and her co-founders identified one of the most overlooked yet critical gaps in healthcare: the lack of meaningful, accessible advance care planning. Under her leadership, Koda Health now supports over 1 million patients through partnerships with organizations like Cigna, Privia, and Houston Methodist.

Lawson Gow, Greentown Labs, 2025 Incubator/Accelerator of the Year

Lawson Gow currently serves as chief strategy officer for Greentown Labs, which was named Incubator/Accelerator of the Year in the 2025 Houston Innovation Awards. Prior to joining Greentown Labs as Head of Houston in 2025, Gow was as a managing partner at Helium Capital, an investment and advisory firm that aims to support founders across the entire lifecycle of entrepreneurship.

He is also the founder of The Cannon, an innovation-infrastructure provider that operates a growing network of innovation hubs for its community of startups, entrepreneurs, investors, and corporate innovators.

Sarah Hein, March Biosciences, 2025 Female-founded Business of the Year

Sarah Hein

Sarah Hein is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging malignancies. Prior to cofounding March Biosciences, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT).

Formerly, she was a cofounder and the vice president of operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also director of research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD in Molecular Biology from Baylor College of Medicine.

Tanu Jain, FlowCare, 2025 Startup of the Year

Tanu Jain

Tanu Jain is a product executive, entrepreneur, founder and CEO of FlowCare, and registered nurse with a track record of building products from zero to global scale. She previously led product at BioIQ before founding FlowCare, a Houston-based period care infrastructure platform making period care a standard in every restroom. In under 16 months, FlowCare has signed deployed across four enterprise customers and impacted more than 1.5 million women.

FlowCare was named Startup of the Year at the 2025 Houston Innovation Awards, and Jain has been recognized with additional honors including the SDG Super Changemaker – Pewter — at the Global Sustainability Awards 2026.

Prabhdeep "Prab" Sekhon, Eclipse Energy, 2025 Energy Transition Business of the Year

Prabhdeep Singh Sekhon

Prabhdeep Singh Sekhon is CEO of Eclipse Energy, an energy technology company transforming depleted oil fields into low-cost, sustainable hydrogen resources through subsurface biotechnology. He brings nearly two decades of global energy experience spanning climate technology, venture capital, private equity, and multi-billion-dollar energy projects across five continents.

Previously, he held leadership roles at NextEra Energy Resources and Hess Corporation. He is also a founder and managing director of GreenLite Resources and a founding member of Cotogna Sports Group. He holds an MBA from Wharton, a Masters in Engineering from Texas A&M, and a BS from the University of Calgary.

Wade Pinder, Product Houston, 2025 Trailblazer Award Winner

Wade Pinder thinks of himself as an "ecosystem wayseeker," helping founders and builders in and around Houston find their footing, understand the landscape, and move through uncertainty with more clarity. Through Product Houston, he works at the intersection of product strategy, founder support, ecosystem mapping, and community-building, with a particular focus on helping people show up in the right rooms before they feel fully ready.

His background includes years in product management at Blinds.com and Home Depot, along with founding and leading the Houston Product Community for six years. He was recognized by as Mentor of the Year in the 2023 Houston Innovation Awards and received the Trailblazer Award in 2025.

Laura Furr Mericas, Interim Editor, InnovationMap

Laura Furr Mericas is interim editor for InnovatonMap.com and EnergyCapitalHTX.com. She is a longtime contributor to both sites and has reported on Houston's innovation ecosystem for InnovationMap since 2020. Previously, she served as web editor and data reporter for Houston Business Journal.

Report: Income for top 1 percent earners in Texas has surged in 2026

money matters

In a state where local billionaires are wealthier than they've ever been, high-earning Texans need to make $73,000 more than they did a year ago if they want to be among the top 1 percent of earners, a new report has revealed.

SmartAsset's study analyzed income thresholds for the top 1, 5, and 10 percent of earners in all 50 states and the District of Columbia, using 2022 IRS data for individual tax return filers (the most recent year available), adjusted to 2026 dollars.

Texas has the 11th highest income threshold, with residents needing to make a minimum of $817,158 to be considered among the top 1 percent of earners statewide. In 2025, Texans needed to make about $744,000 to be among the top 1 percent.

For comparison, residents living in the nation's capital must make at least $1.16 million to qualify as top 1 percent earners. The District of Columbia led the nation with the highest income threshold to be a top earner.

To be considered among the top 5 percent of earners in Texas, a resident would need to make $312,671. The income threshold to be considered among the top 10 percent is $210,609.

SmartAsset additionally found that 128,130 Texas residents qualified as top 1 percent earners in 2022. Nationally, the report estimated that fewer than 2 million households earn enough to be considered among the top 1 percent of earners nationwide, but 23 million households rank among the top 10 percent.

"In some places, households can enter the top 1 percent at income levels that fall well below the threshold elsewhere, reflecting an uneven landscape of wages and wealth," the report said.

A separate SmartAsset study that tracked the upper and lower thresholds for middle class households found Houston residents need to make anywhere from $42,907 to $128,722 to maintain their middle class status.

The top 10 states with the highest thresholds to be considered in the top 1 percent of earners in the U.S. are:

  • No. 1 – District of Columbia ($1,156,664)
  • No. 2 – Connecticut ($1,147,898)
  • No. 3 – Massachusetts ($1,006,921)
  • No. 4 – California ($987,325)
  • No. 5– New Jersey ($969,976)
  • No. 6 – New York ($959,562)
  • No. 7 – Florida ($956,449)
  • No. 8 – Washington ($903,303)
  • No. 9 – Colorado ($828,772)
  • No. 10 – Wyoming ($819,014)
---

This article originally appeared on CultureMap.com.